



2-4-04

1614 \$

FEE TRANSMITTAL

Application Number 09/868,261
Filing Date October 5, 2001
Confirmation No. Unknown
Inventor(s) John P. McKearn et al.
Attorney Docket Number PHA 2005.1 (3167/8Z/US)

Art Unit 1614

METHOD OF PAYMENT

1. ☐ The Commissioner is hereby authorized to charge the indicated fees to Deposit Account No. 19-1345.
- ☒ The Commissioner is hereby authorized to charge any additional fees required under 37 CFR 1.16 and 1.17 to Deposit Account No. 19-1345.
- ☐ Applicant claims small entity status.
2. ☒ Check Enclosed. The Commissioner is hereby authorized to charge any under payment or credit any over payment to Deposit Account No. 19-1345.

FEE CALCULATION

1. ☐ BASIC FILING FEE Subtotal (1) \$ _____
(Type: _____)
2. ☐ EXTRA CLAIM FEES Subtotal (2) \$ _____
Total Claims _____
Independent Claims _____
Multiple Dependent Claims _____
3. ☒ ADDITIONAL FEES Subtotal (3) \$ 180.00
☐ Surcharge - late filing fee or oath
☐ Surcharge - late provisional filing fee or cover sheet
☐ Extension for reply within _____ month
☐ Notice of Appeal
☐ Filing a Brief in Support of an appeal
☐ Request for ex parte Reexamination
☐ Petitions to the Commissioner
☒ Submission of Information Disclosure Statement
☐ Recording each patent assignment per property
☐ Request for Continued Examination
☐ Other: _____


TOTAL AMOUNT OF PAYMENT \$ 180.00


Kathryn J. Doty, Reg. No. 40,593

February 3, 2004
Date

KJD/CDS/msc

Express Mail Label No. EV 416453234 US



PHA 2005.1 (3167/8Z/US)
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of John P. McKearn et al. Art Unit 1614
Serial No. 09/868,261
Filed October 5, 2001
Confirmation No. Unknown
For METHOD OF USING A CYCLOOXYGENASE-2 INHIBITOR AND AN INTEGRIN
ANTAGONIST AS A COMBINATI8ON THERAPY IN THE TREATMENT OF
NEOPLASIA

February 3, 2004

COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VIRGINIA 22313-1450

SIR:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

* In accordance with 37 C.F.R. 1.97 and 1.98 and MPEP 609, and in compliance with the duty of disclosure set forth in 37 C.F.R. 1.56, Applicants submit copies of the references listed on the attached PTO/SB/08A for consideration by the Patent and Trademark Office in the above-entitled application and to be made of record therein.


In preparation of this Supplemental Information Disclosure Statement, Applicants determined that approximately 1,000 references were cited in the application. In an effort to reduce the burden on the Office, each reference was briefly reviewed by an attorney. This review eliminated any reference that was determined to be irrelevant or merely cumulative. If the Office would like a copy of the eliminated references, they can be provided at the Office's request.

* A check in the amount of \$180.00 is enclosed to cover the fee specified in 37 CFR §1.17(p) for submission of this

Supplemental Information Disclosure Statement. The Commissioner is hereby authorized to charge any under payment or credit any over payment to Deposit Account No. 19-1345.

* Also enclosed is Applicants' executed Power of Attorney.

Respectfully submitted,



Kathryn J. Doty, Reg. No. 40,593
SENNIGER, POWERS, LEAVITT & ROEDEL
One Metropolitan Square, 16th Floor
St. Louis, Missouri 63102
(314) 231-5400

KJD/msc
*Enclosures

Express Mail Label No. EV 416453234 US

PTO/SB/08A			Complete if Known		
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	09/868,261	
			Filing Date	October 5, 2001	
			Confirmation Number	Unknown	
			First Named Inventor	John P. McKearn et al.	
			Group Art Unit	1614	
			Examiner Name	Unknown	
Sheet	1	of	2	Attorney Docket No.	PHA 2005.1 (3167/8Z/US)

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code ² (if known)		
	175.	6,077,850		Carter et al.	06-20-2000
	176.	6,087,392		Reiter	07-11-2000
	177.	6,110,964		Robinson	08-29-2000
	178.	6,114,361		Robinson et al.	09-05-2000
	179.	6,156,798		Reiter	12-05-2000
	180.	6,214,870	B1	McClure et al.	04-10-2001
	181.	6,277,878	B1	Nakao et al.	08-21-2001
	182.	6,294,558	B1	Ando et al.	09-25-2001
	183.	6,303,628	B1	Nakao et al.	10-16-2001

FOREIGN PATENT DOCUMENTS


Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T ⁶
		Office	Number ⁴	Kind Code ² (if known)			
	184.	EP	1 081 137	A1	Pfizer Products Inc.	03-07-2001	
	185.	EP	1 088 550	A1	Pfizer Products Inc.	04-04-2001	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08A SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) 				Complete if Known	
				Application Number	09/868,261
				Filing Date	October 5, 2001
				Confirmation Number	Unknown
				First Named Inventor	John P. McKearn et al.
				Group Art Unit	1614
				Examiner Name	Unknown
Sheet	2	of	2	Attorney Docket No.	PHA 2005.1 (3167/8Z/US)

	186.	EP	1 104 759	A1	Pfizer Products Inc.	06-06-2001	
	187.	EP	1 104 760	A1	Pfizer Products Inc.	06-06-2001	
	188.	EP	1 134 215	A1	Pfizer Products Inc.	09-19-2001	
	189.	EP	1 138 680	A1	Pfizer Products Inc.	10-04-2001	
	190.	WO	97/20824	A1	Agouron Pharmaceuticals, Inc.	06-12-1997	
	191.	WO	98/03516	A1	Pfizer Inc.	01-29-1998	
	192.	WO	98/30566	A1	Pfizer Inc.	07-16-1998	
	193.	WO	98/47890	A1	G.D. Searle & Co.	10-29-1998	
	194.	WO	00/09485	A1	Pfizer Products Inc.	02-24-2000	
	195.	WO	00/09492	A1	Pfizer Products Inc.	02-24-2000	
	196.	WO	00/73294	A2	Pfizer Products Inc.	12-07-2000	
	197.	WO	01/12611	A1	Pfizer Products Inc.	02-22-2001	
	198.	WO	01/40216	A1	Pfizer Products Inc.	06-07-2001	

OTHER ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.